Novartis Forecasts 5% Yearly Sales Growth

Healthcare suppliers should note rising peak-sales targets for several established Novartis drugs.

Updated on Nov. 19, 2026 in Healthcare

Isometric editorial illustration of a rising diagonal stack of identical white cylindrical forms on a cream field, suggesting steady measured growth in pharmaceutical sales.
Swiss drugmaker Novartis forecast average net sales growth of 5% a year from 2026 to 2031 and raised peak-sales estimates for Kesimpta, Scemblix, and Leqvio. AI Illustration. Upload story photo >

Swiss drugmaker Novartis forecasts average net sales growth of 5% per year from 2026 to 2031, excluding exchange-rate effects, and raised peak sales estimates for several of its drugs. The company is a major pharmaceutical player, and the outlook signals where healthcare revenue is expected to concentrate over the medium term.

Why it matters

The forecast reflects confidence that existing drugs will keep gaining sales alongside new launches, a pattern that shapes pricing, supply, and partnership decisions across the healthcare sector. Upward revisions to specific products also show where drugmakers expect demand to grow fastest.

Novartis projects 5% average annual net sales growth through 2031, excluding exchange-rate effects. Peak sales forecasts rose to $8 billion each for Kesimpta and Rhapsido, while nine on-market products could each reach $3 billion to $10 billion in annual sales.

The players

Novartis

Swiss pharmaceutical company with a large portfolio of branded prescription drugs, whose revenue depends on sustaining sales of established products while launching new ones.

The details

Novartis expects growth to come from two sources: rising sales of drugs already on the market and new products coming to market. The company raised its peak sales forecasts for Kesimpta, Scemblix, and Leqvio, the first two from $6 billion and $4 billion respectively, which are revisions to prior estimates rather than new launches. The company says its core operating margin is on track to recover to above 40% by 2029.

Timeline

  1. 2026 to 2031: projected period of 5% average annual net sales growth.

  2. 2029: expected year for core operating margin to recover above 40%.

Market Landscape

The revisions show a major drugmaker raising its ceiling for products already on the market rather than relying only on pipeline launches. That approach sets a benchmark for how established pharmaceutical companies position their long-term sales outlook against competitors.

Operators in healthcare supply, distribution, and services should watch for demand shifts tied to the growth of specific drugs. Finance and procurement teams may find it useful to track how drugmaker revenue plans translate into contracting and pricing terms.

The takeaway

Medium-term revenue plans from large drugmakers increasingly rest on growing established products. Operators should track how such forecasts affect supplier and contracting conditions in the coming quarters.

Further reading

For broader context on how drugmakers plan revenue and pricing, explore our Healthcare coverage.